


Remington-Davis Investigators & Therapeutic Areas of Research Interest



Edward M. Cordasco, Jr., DO, FCCP

Internal Medicine, Pulmonology

- Chronic obstructive pulmonary disease, asthma, chronic bronchitis
- Respiratory infections
- Cardiovascular risk and outcomes (hypertension, atrial fibrillation, hyperlipidemia)
- Type 2 diabetes and metabolic/weight-loss studies
- Gastroesophageal reflux disease, irritable bowel syndrome, inflammatory bowel disease
- Adult vaccines (Norovirus, Clostridioides difficile, Staphylococcus aureus)
- Outpatient medical devices

Brian R. Zeno, MD, FCCP

Pulmonology

- Chronic obstructive pulmonary disease, asthma, chronic cough
- COVID-19 and outpatient respiratory therapeutics
- Cardiopulmonary disease
- Gastroesophageal disorders (heartburn, reflux)
- Adult vaccines (COVID-19, Escherichia coli)
- Respiratory and outpatient devices

Roy C. St. John, MD

Pulmonology

- Chronic obstructive pulmonary disease, asthma, chronic bronchitis, chronic cough
- Type 2 diabetes and metabolic/obesity studies
- Hypertension and cardiovascular risk reduction
- Gastrointestinal disorders (diarrhea-predominant irritable bowel syndrome, reflux disease)
- Outpatient diagnostics and sensor-based devices

Ian Baird, MD, FACP

Infectious Disease & Immunology

- Adult vaccines (Clostridioides difficile, Staphylococcus aureus, Botulism, Escherichia coli)
- Outpatient infectious diseases
- Immunologic, biologic, and vaccine therapeutics
- Internal medicine conditions (hypertension, atrial fibrillation, diabetes)

Kevin L. Schroeder, MD

Nephrology

- Chronic kidney disease, renal impairment, polycystic kidney disease
- Cardiorenal disease and hypertension
- Diabetes and metabolic disease
- Complicated urinary tract infection
- Renal-focused outpatient studies

Krishna M. Rayapudi, MD

Gastroenterology

- Gastroesophageal reflux disease and erosive esophagitis
- Functional gastrointestinal disorders (diarrhea-predominant and constipation-predominant irritable bowel syndrome)
- Inflammatory bowel disease
- Fatty liver disease, metabolic dysfunction-associated steatohepatitis, hepatitis
- Gastrointestinal infections (*Clostridioides difficile*, *Helicobacter pylori*)

Michelle C. Chambers, MD, FAAD

Dermatology

- Atopic dermatitis, psoriasis, vitiligo, alopecia
- Inflammatory and pigmentary skin disease
- Photodynamic therapy
- Dermatology imaging and device studies



Our Services

Therapeutic Areas

- Vaccine Studies
- General Medicine/Internal Medicine
- Endocrinology Studies
- Dermatology Studies
- Gastroenterology Studies
- Nephrology Studies
- Pulmonary Studies
- Phase 1

Efficiency at Every Step

- Contract turnaround = 24 hours
- Regulatory packet completion = 72 hours
- eRegulatory for instant access
- eSource for realtime monitoring
- Greenlight to first patient = 1 week
- Data entry/query resolution = 24 hours

Proof of Rapid Enrollment

- Phase 1 – 36-hour infusion, 5-day sequestration, 85 subjects in 3 months
- COVID-19 Treatment – 235 subjects in 6 months
- Diabetes Device – 360 subjects in 6 weeks
- Migraine – 60 subjects in 9 days
- Vaccine – 80 specialty subjects in 2 months

“You and your team are doing fantastic with the STRIVE study. I would clone your site if I could! Such a pleasure to work with your team.”



Remington-Davis, Inc.
1335 Dublin Road, Suite 106A
Columbus, OH 43215

 (614) 487-2560

 www.remdavis.com

